多替阿巴拉米片是哪个国家的？

On January 22, 2018, British GlaxoSmithKline (GSK) announced that its controlling joint venture ViiV Healthcare will be used to treat HIV The single-pill compound preparation Triumeq (chemical name: Triumeq), which is based on the new generation of integrase inhibitor Triumeq (chemical name: dolutegravir), is officially launched in mainland China. This drug is the only three-in-one compound drug containing dolutegravir. It takes one tablet once a day and has the characteristics of high efficiency, good tolerance, high resistance barrier and few drug interactions.

This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Retail price 2880$/month. Trimax is a medicine containing three active ingredients, used to treat HIV infection in adults and children over 12 years of age weighing more than 40 kilograms. Trimax contains three ingredients: abacavir, lamivudine and dolutegravir. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs); dolutegravir is an integrase inhibitor (INIs). Existing research shows that one year (48 weeks) after HIV infection treatment, 93% of HIV-infected patients turned negative.

Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China\Hong Kong, said, "Through effective HIV drug treatment, we can see that the life spans of AIDS patients and healthy people are getting closer and closer. Therefore, drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time, on the Chinese market. The approval of the drug fills this gap and meets the urgent need for convenient medication use by doctors and patients."